Phase 2 Open Label, Multicenter Study Evaluating CRG-022, a CD22-directed Autologous CAR T-cell Therapy, in Patients (pts) with Relapsed/refractory (R/R) Large B-cell Lymphoma (LBCL) after CD19-directed CAR T-cell Therapy.
Journal of Clinical Oncology(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined